OpGen Entered Into An Agreement To Sell Its Commercial Customer Contracts And Installed Base Of Unyvero Systems To Camtech Pte Ltd For $218,000
OpGen Entered Into An Agreement To Sell Its Commercial Customer Contracts And Installed Base Of Unyvero Systems To Camtech Pte Ltd For $218,000
The Chairman and CEO of OpGen, David Lazar, commented: "These transactions are consistent with our strategy of preparing OpGen for a potential strategic transaction, including a potential reverse merger of a private company into OpGen. We believe a strategic transaction would be an attractive proposition to OpGen stockholders who could benefit from future value growth."OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings.
OpGen公司（納斯達克股票代碼：OPGN，“OPGen” 或 “公司”）））今天宣佈，它已達成協議，以21.8萬美元的價格將其商業客戶合同和Unyvero系統的安裝基礎出售給新加坡家族辦公室Camtech Pte Ltd（“Camtech”）。該交易是在Curetis破產程序中Camtech先前收購了Curetis GmHH（“Curetis”）、該公司的子公司Unyvero的所有資產、權利和業務之後進行的。
In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Ares Genetics' insolvency proceedings. Since the sales of both Curetis and Ares Genetics' assets occurred as part of their insolvency proceedings, OpGen did not participate or have any involvement in such transactions.
此外，作爲Ares Genetics破產程序的一部分，該公司的子公司Ares Genetics GmbH將其所有資產，包括AresDB數據庫和知識產權組合出售給了Biomerieux S.A.。由於出售Curetis和Ares Genetics的資產是其破產程序的一部分，因此OpGen沒有參與或參與此類交易。
OpGen plans to work with Camtech and the Curetis team during the upcoming months to transfer and transition its U.S. Unyvero customers and business. OpGen also offered Camtech the opportunity to acquire its remaining inventory of Unyvero systems for up to an additional $176,000. Until such sale for the remaining inventory is completed, OpGen will maintain commercial operations and service support for the Unyvero systems.
OpGen計劃在未來幾個月內與Camtech和Curetis團隊合作，轉移和過渡其美國Unyvero客戶和業務。OpGen還爲Camtech提供了以高達17.6萬美元的價格收購其剩餘的Unyvero系統庫存的機會。在剩餘庫存的銷售完成之前，OpGen將維持對Unyvero系統的商業運營和服務支持。
The Chairman and CEO of OpGen, David Lazar, commented: "These transactions are consistent with our strategy of preparing OpGen for a potential strategic transaction, including a potential reverse merger of a private company into OpGen. We believe a strategic transaction would be an attractive proposition to OpGen stockholders who could benefit from future value growth."
OpGen董事長兼首席執行官戴維·拉扎爾評論說：“這些交易符合我們的戰略，即讓OpGen爲潛在的戰略交易做好準備，包括可能將一傢俬營公司反向併入OpGen。我們認爲，對於可能從未來價值增長中受益的OpGen股東來說，戰略交易將是一個有吸引力的提議。”
譯文內容由第三人軟體翻譯。